Sulfanilamide

Sulfanilamide

SCHEMBL4188099

CC.Nc1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfanilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 16/20 0.90
CA9 Q16790 14/20 0.90
CA1 P00915 13/20 0.90
CA12 O43570 12/20 0.90
CA7 P43166 6/20 0.90
CA14 Q9ULX7 5/20 0.90
CA5A P35218 5/20 0.90
CA5B Q9Y2D0 5/20 0.90
CA6 P23280 4/20 0.90
TSHR P16473 3/20 0.90
CA4 P22748 3/20 0.90
CA13 Q8N1Q1 2/20 0.90
USP2 O75604 1/20 0.90
TDP1 Q9NUW8 1/20 0.90
AGO2 Q9UKV8 1/20 0.90
CA3 P07451 2/20 0.61
HTT P42858 1/20 0.61
LMNA P02545 1/20 0.59
MPO P05164 1/20 0.59
CYP3A4 P08684 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfanilamide SCHEMBL30659052 0.95 CA2 (1.00) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL740 0.95 CA2 (1.00) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL31544839 0.95 CA2 (1.00) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL2798899 0.95 CA2 (1.00) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL27364276 0.92 CA2 (0.85) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL28201481 0.92 CA2 (0.85) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL3273308 0.92 CA2 (0.94) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL5894222 0.92 CA2 (0.94) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL8030126 0.92 CA2 (0.94) CA2CA9CA1CA12CA7
Sulfanilamide SCHEMBL22501553 0.92 CA2 (0.94) CA2CA9CA1CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109251588-A Inorganic nano material ink and its preparation method and application, QLED device TCL集团股份有限公司 2019-01-22 CN claimed
CN-104918945-B Tricyclic fused thiophene derivatives as JAK inhibitors 因赛特公司 2018-01-05 CN claimed
EP-3247703-A1 IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) 2017-11-29 EP claimed
WO-2016151104-A1 IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2016-09-29 WO claimed
WO-2016116589-A1 IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2016-07-28 WO claimed
EP-4313969-A1 N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF Bridge Biotherapeutics, Inc. (KR) 2024-02-07 EP disclosed
EP-4034107-A1 JAK INHIBITORS Vimalan Biosciences, Inc. (US) 2022-08-03 EP disclosed
EP-3898637-A1 RAPAMYCIN DERIVATIVES Novartis AG (CH) 2021-10-27 EP disclosed
WO-2020128861-A1 RAPAMYCIN DERIVATIVES NOVARTIS AG (CH) 2020-06-25 WO disclosed
CN-110520409-A Compounds and compositions for intracellular delivery of therapeutic agents MODERNATX INC 2019-11-29 CN disclosed
CN-110483423-A P2X4 receptor antagonist NIPPON CHEMIPHAR CO 2019-11-22 CN disclosed
CN-105934246-B Tetrahydroquinoline compositions as BET bromodomain inhibitors 福马疗法公司 2019-10-22 CN disclosed
CN-104321320-B Prepare statin facilitates method 意大利合成制造有限公司 2017-05-31 CN disclosed
US-20170071946-A1 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES PFIZER INC. (US) 2017-03-16 US disclosed
US-9518052-B2 Pyrazolopyridines and pyrazolopyrimidines PFIZER INC. (US) 2016-12-13 US disclosed
WO-2016151104-A1 IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2016-09-29 WO disclosed
WO-2016125086-A1 PROCESSES FOR THE PREPARATION OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LAURUS LABS PRIVATE LIMITED (IN) 2016-08-11 WO disclosed
WO-2016116589-A1 IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2016-07-28 WO disclosed
US-20150329542-A1 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES PFIZER INC. 2015-11-19 US disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329542-A1 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES HRH2, HRH4, HRH1 CA2 361/4885CA9 1782/4885CA1 2724/4885
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 CA2 1136/4885CA9 4317/4885CA1 1637/4885
US-20170071946-A1 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES HRH2, HRH4, HRH1 CA2 361/4885CA9 1782/4885CA1 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.